Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$6 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-1.1 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
3.2
Industry P/E
27.54
EV/EBITDA
-0.9
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-4.6
Face value
--
Shares outstanding
914,234
CFO
$-84.33 Mln
EBITDA
$-75.11 Mln
Net Profit
$-92.55 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Titan Pharmaceuticals (TTNP)
| 36.5 | -12.6 | 25.9 | -35.9 | -25.2 | -53.2 | -56.1 |
|
BSE Sensex
| 3.7 | -1.6 | 9.6 | 5.9 | 14.3 | 19.1 | 11.9 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Titan Pharmaceuticals (TTNP)
| -59.9 | -47.6 | -23.5 | -69.0 | -43.5 | -85.5 | -83.0 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Titan Pharmaceuticals (TTNP)
|
4.5 | 6.1 | 0.0 | -4.2 | -27,350.0 | -164.8 | -- | 3.2 |
| 20.7 | 5,221.1 | 459.4 | 206.8 | 25.6 | 68.3 | 26 | 13.3 | |
| 31.1 | 3,857.8 | 8.9 | -369.2 | -4,861.1 | -26.1 | -- | 2.9 | |
| 105.0 | 5,321.5 | 432.2 | -278.3 | -64.1 | -380.9 | -- | 100.0 | |
| 57.1 | 10,961.9 | 2,937.8 | 523.9 | 23.2 | 9.3 | 21.2 | 1.9 | |
| 39.4 | 7,414.9 | 127.4 | -668.0 | -432.9 | -- | -- | 123.7 | |
| 70.6 | 7,554.7 | 685.5 | 132.9 | 15.6 | 20.1 | 60.4 | 11.0 | |
| 13.8 | 7,087.1 | 4,427.0 | 373.0 | -0.7 | 5.8 | 18.5 | 1.1 | |
| 84.2 | 4,206.2 | 1,137.8 | 214.6 | 29.2 | 12.3 | 19.6 | 2.3 | |
| 9.1 | 10,539.7 | 14,317.0 | -3,790.1 | -23.7 | -21.4 | -- | 0.7 |
Titan Pharmaceuticals, Inc. does not have significant operations. Previously, it was engaged in the development of therapeutics for the treatment of chronic diseases. Titan Pharmaceuticals, Inc. was founded in 1991 and is based in New York, New York.... Address: 10 East 53rd St., New York, NY, United States, 10022 Read more
CEO & Principal Financial Officer
Mr. David Elliot Lazar
CEO & Principal Financial Officer
Mr. David Elliot Lazar
Headquarters
New York, NY
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Titan Pharmaceuticals Inc (TTNP) stood at $ 2 Mln as on 31-Mar-25
The share price of Titan Pharmaceuticals Inc (TTNP) is $4.45 (NASDAQ) as of 13-Jun-2025 10:36 EDT. Titan Pharmaceuticals Inc (TTNP) has given a return of -25.23% in the last 3 years.
Titan Pharmaceuticals Inc (TTNP) has a market capitalisation of $ 6 Mln as on 12-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Titan Pharmaceuticals Inc (TTNP) is 3.22 times as on 12-Jun-2025, a 33% discount to its peers’ median range of 4.78 times.
Since, TTM earnings of Titan Pharmaceuticals Inc (TTNP) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Titan Pharmaceuticals Inc (TTNP) and enter the required number of quantities and click on buy to purchase the shares of Titan Pharmaceuticals Inc (TTNP).
Titan Pharmaceuticals, Inc. does not have significant operations. Previously, it was engaged in the development of therapeutics for the treatment of chronic diseases. Titan Pharmaceuticals, Inc. was founded in 1991 and is based in New York, New York. Address: 10 East 53rd St., New York, NY, United States, 10022
The CEO & director of Mr. David Elliot Lazar. is Titan Pharmaceuticals Inc (TTNP), and CFO & Sr. VP is Mr. David Elliot Lazar.
There is no promoter pledging in Titan Pharmaceuticals Inc (TTNP).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,089
|
|
|
1,022
|
|
|
742
|
|
|
722
|
|
|
667
|
|
|
542
|
|
|
485
|
|
|
419
|
|
|
415
|
| Titan Pharmaceuticals Inc. (TTNP) | Ratios |
|---|---|
|
Return on equity(%)
|
-164.8
|
|
Operating margin(%)
|
-27350
|
|
Net Margin(%)
|
-42090
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Titan Pharmaceuticals Inc (TTNP) was $0 Mln.
$-0.03
(
